Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Louis Lange sold 28,186 shares of NewAmsterdam Pharma stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $29.41, for a total value of $828,950.26. The transaction was disclosed in a filing with the SEC, which is available at this link.

NewAmsterdam Pharma Trading Up 0.3%

NAMS stock opened at $31.35 on Thursday. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $42.00. The business’s 50 day simple moving average is $33.34 and its 200 day simple moving average is $33.35. The firm has a market capitalization of $3.60 billion, a PE ratio of -18.12 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. As a group, sell-side analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

Several large investors have recently made changes to their positions in the company. Atle Fund Management AB raised its stake in NewAmsterdam Pharma by 23.2% during the third quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock worth $5,507,000 after acquiring an additional 36,402 shares in the last quarter. Jennison Associates LLC increased its position in NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares in the last quarter. Keybank National Association OH bought a new position in NewAmsterdam Pharma in the 3rd quarter valued at approximately $455,000. Franklin Resources Inc. boosted its position in NewAmsterdam Pharma by 30.6% in the second quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock valued at $6,053,000 after buying an additional 78,300 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its position in NewAmsterdam Pharma by 18.8% in the third quarter. Handelsbanken Fonder AB now owns 405,800 shares of the company’s stock valued at $11,541,000 after buying an additional 64,200 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on NAMS shares. Guggenheim lifted their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Stifel Nicolaus raised their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Leerink Partners reissued an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Finally, Needham & Company LLC lifted their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $47.10.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.